Abstract: Introduction: Combination of cytotoxic drugs was suggested to decrease the rate of non-responders in severe ocular lesions of Behcet’s disease (BD). We present here our preliminary data with low dose pulse Cyclophosphamide (LDP) and Azathioprine (AZA) in the treatment of posterior uveitis (PU) and/or retinal vasculitis (RV) of BD. Patients & methods: Twelve BD patients with PU and RV were selected. They all received LDP as 0.5 g/m2 body surface/month ...
Abstract: Background: The purpose of this study was to evaluate the difference between oral aphthae in Behcet’s Disease (BD) and recurrent aphthous stomatitis (RAS). Methods: In a prospective study 56 cases of BD and 133 RAS were evaluated consecutively. Sex, age of onset, frequency of aphthous lesions, their duration and their mean number at each attack, pathergy test, HLA-B5, HLA-B51 and HLA-B27 were evaluated in both groups. Comparison was made by Student ...
Abstract: Introduction: Pyoderma gangrenosum (PG) like lesion is a Behcet’s disease (BD) skin lesion, which is seen very exceptionally. We report here 2 cases with unusual severe and extensive skin lesions, having an intensive hypersensitivity to needle injection, inducing new lesions. Cases report: The first case is a 42 years old man with a history of 5 years recurrent bipolar aphthosis, skin pustulosis, ocular lesions, and articular involvement. After ...
Abstract: Introduction: Ocular manifestations are seen more frequently in men than women (62% men, 49% women). The difference is statistically significant (p
Abstract: Introduction: The natural course of eye lesions is well known, leading to sever loss of vision or blindness. The cumulative nature of eye lesions during successive attacks, leads to gradual loss of visual acuity (VA). The aim of this study was to evaluate the effect of the delay in aggressive treatment on the VA and its long-term outcome. Materials and Methods: All Behcet’s patients of the treatment registry (1009 ...
Abstract: Introduction: It is known from long date that some manifestations are seen more frequently in men than women and in some of them the difference may be statistically significant. The aim of this study was to address that issue and to find if a statistical difference was of any clinical relevance or significance Materials and Methods: All patients of the BD registry (4717 at January 20, 2002) entered the ...
Abstract: Introduction: methotrexate in weekly low dose pulse of 7.5 mg has long proved its efficacy in the treatment of ocular lesions. During the 1998 ACR congress where we presented our data on 262 patients it was suggested the high dose of 15 mg. This is the short-term result of that study. Materials and Methods: MTX was used as 15 mg weekly. Prednisolone was associated as 0.5 mg/kg/ daily. The visual ...
Abstract: Background: Our purpose was to show different aspects of the muco-cutaneous lesions of Behcet’s disease (BD). Although they are not specific, they constitute the major symptoms in all sets of diagnosis criteria for BD. Methods: Description of muco-cutaneous lesions seen during 12 years follow up in 4605 patients. Results: 1- Mucous-membrane lesions: Recurrent oral aphthosis (OA) is the most important and frequent lesion of BD. It resembles the other OA of other ...
Abstract: Introduction: Ocular lesions of Behcet’s disease (BD) progress by recurrent attacks and remission. Their natural history, without treatment, is toward severe loss of vision or blindness. We presented last year a work to the ACR meeting on the long-term outcome of visual acuity (VA) in BD. The data showed that the final VA was related to the baseline VA (before the treatment), suggesting that a delay in aggressive treatment may ...
Abstract: Introduction: It is known from long date that some manifestations are seen more frequently in men than women and in some of them the difference may be statistically significant. The aim of this study was to address that issue and to find if a statistical difference was of any clinical relevance or significance Materials and Methods: All patients of the BD registry (4717 at January 20, 2002) entered the ...